Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
colchicine + dapsone
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of colchicine and dapsone used primarily for treating complex aphthosis and colchicine-resistant Familial Mediterranean Fever (FMF). This combination has shown significant effectiveness in patients who don't respond adequately to colchicine alone. The medications work through different but complementary anti-inflammatory mechanisms, with colchicine typically used as first-line therapy and dapsone added for enhanced efficacy.
02
Targets
DHPS (Dihydropteroate synthase)MPO (Myeloperoxidase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on colchicine + dapsone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on colchicine + dapsone.